Business Wire

MERCY-SHIPS

31.5.2022 07:32:04 CEST | Business Wire | Press release

Share
H.E. President Macky Sall Leads Inauguration of the World’s Largest Purpose-built Hospital Ship, the Global Mercy™

H.E. President of Senegal Macky Sall has inaugurated the world’s largest purpose-built hospital ship and committed to accelerate access to surgical, obstetric and anesthetic care for the nations of Africa. Ceremonies commemorated more than 30 years of service in Africa. International humanitarian organization Mercy Ships and its partners in Africa used the opportunity to come together in an unprecedented and strategic effort to improve access to safer surgery across the continent through a series of milestone events.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220530005472/en/

Representatives from Cameroon, the Union of Comoros, Congo Brazzaville, The Gambia, Guinea-Bissau, and Senegal, gathered on board the Global Mercy to approve a strategic road map to improve surgical care for African nations by 2030, where an estimated 93% of sub-Saharan Africa still lack access to safe surgery.

H.E. President Macky Sall greeted the Heads of State, saying, “We, heads of states present this day, have adopted the Dakar Declaration, which is the result of the meticulous work of our ministers and experts on access to surgical, obstetric and aesthetic care. As President in Office for the African Union, I commit to bring the Dakar Declaration to the summit of heads of state and African governments.”

Gert van de Weerdhof, Mercy Ships Chief Executive Officer said, “At the end of a difficult week for Senegal and for all of us after the tragic events that happened; today, I want to greet you all on this special day here in Dakar, Senegal. The inauguration of the Global Mercy is only one part of the reason we celebrate today. Big decisions have been made here in Dakar.”

President of the Union of the Comoros, Azali Assoumani said, “I pay tribute to Senegal as well as the personnel of Mercy Ships for their commitment to this mission. I applaud this model cooperation contributing to the strengthening of our surgical, obstetric, and anesthetic systems in Africa.”

The Dakar Declaration is an historic agreement following foundational discussions from an International Symposium in Senegal held May 4 – 6, 2022 where experts and ministers of health from 29 African nations met to put forward their commitment to advancing access to surgical, obstetric, and anesthetic care. The result of the Symposium brought a fresh initiative to draft a clear path toward safer and wider access to surgical care in Africa by 2030. Symposium members shared knowledge of their countries’ surgical care situations, addressed gaps and challenges in their national surgical, obstetric and anesthetic plans, and developed new strategies for implementation and capacity building. Prior to the International Symposium, a baseline assessment was carried out with each country and evaluated by a scientific committee.

A first of its kind in Africa, this study has so far collected data about the availability, access, and operation of surgical, obstetric, and anesthetic healthcare systems in 29 of the 47 nations of WHO’s sub-Saharan African region. The survey provides critical insights into Africa’s healthcare systems from the perspective of district hospitals, particularly in the area of surgery. The World Health Organization will leverage the results of the study to complete the ongoing situational analysis of clinical and hospital services, as well as develop and finalize the regional strategy for strengthening clinical and hospital services in Africa.

The comprehensive preliminary report developed by members of the scientific committee led to the drafting of a roadmap to scale up investment in the strengthening of surgical, obstetric, anesthetic, and nursing care in Africa, in line with the Sustainable Development Goals (SDG). A draft Dakar Declaration was prepared and endorsed by the Ministers of Health and approved by visiting African Heads of State.

The new hospital ship, Global Mercy ™ is 174 meters long, 28.6 meters wide and has space for 200 patients, six operating rooms, one laboratory, general outpatient clinics, a dental clinic, and an eye clinic. The hospital decks cover a total area of 7,000 square meters and contain the latest training facilities. When in full service, the ship will be able to accommodate up to 950 people when docked, including crew members and volunteers from all over the world.

A recording of the inauguration ceremony can be found here: https://www.youtube.com/watch?v=HylOGBYaX-0 .

ABOUT MERCY SHIPS:

Global health for the last two decades has focused on individual diseases, while surgical care in low-resource countries has not received the attention it needs. Lack of surgical care resulted in almost 17 million deaths annually.

Mercy Ships is an international faith-based organization that operates hospital ships to deliver free, world-class healthcare services, medical capacity building, and health system strengthening to those with little access to safe surgical care. Since 1978, Mercy Ships has worked in more than 55 countries, with the last three decades focused entirely on partnering with African nations. Each year, volunteer professionals from over 60 countries serve on board the world’s two largest non-governmental hospital ships, the Africa Mercy® and the Global Mercy™. Professionals such as surgeons, dentists, nurses, health trainers, cooks, and engineers dedicate their time and skills to the cause. Mercy Ships has offices in 16 countries and an Africa Bureau. For more information, visit mercyships.org and follow us @MercyShips on social media.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release

Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi

Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme

Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release

Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release

On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-

Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release

Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye